
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : rhBMP-2
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Preclinical
Sponsor : Mercia Ventures
Deal Size : $9.8 million
Deal Type : Funding
Locate Bio Raises £9.2 Million for LDGraft Clinical Study
Details : LDGraft (rhBMP-2) by Locate Bio is undergoing early clinical trials for treating degenerative disc disease.
Product Name : LDGraft
Product Type : Protein
Upfront Cash : Undisclosed
April 29, 2024
Lead Product(s) : rhBMP-2
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Preclinical
Sponsor : Mercia Ventures
Deal Size : $9.8 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : rhBMP-2
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Mercia Asset Management
Deal Size : $13.7 million
Deal Type : Funding
Locate Bio Closes £10 million Funding Round
Details : The funding will be used to advance Locate Bio’s proprietary pipeline, including its lead product called LDGraft, a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease.
Product Name : LDGraft
Product Type : Protein
Upfront Cash : Undisclosed
September 03, 2021
Lead Product(s) : rhBMP-2
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Mercia Asset Management
Deal Size : $13.7 million
Deal Type : Funding
